Evidence map›Paper›PMID 19589867›Full record

ArticleEndocrinology2009

Remission of type 1 diabetes after anti-CD3 antibody treatment and transplantation of embryonic pancreatic precursors.

Salma Begum, Wei Chen, Kevan C Herold, Virginia E Papaioannou

Open access · bronzeAbstract read
In one paragraph

Article in Endocrinology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.8field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Biologic agents in islet transplantation.Current diabetes reports · 2013
    Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Salma BegumDepartment of Genetics and Development, HHSC 1402, Columbia University, New York, New York 10032, USA.
Wei Chen
Kevan C Herold
Virginia E Papaioannou
Yale University · USColumbia University · US

Funding

Islet Growth in NOD Mice Tolerant to Autoimmune DiabetesR01DK068678 · NIDDK · YALE UNIVERSITY · PI HEROLD, KEVAN C · 2004 to 2005
$569k
Islet growth in NOD mice tolerant to autoimmune diabetesR01DK068661 · NIDDK · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI PAPAIOANNOU, VIRGINIA E. · 2004 to 2005
$403k
NIDDK NIH HHS R01 DK068661NIDDK NIH HHS R01 DK068678
6 · The paper itself

Abstract

Type 1 diabetes (T1D) mellitus is characterized by progressive autoimmune destruction of insulin producing beta-cells of the pancreatic islets of Langerhans. Cure of the disease will require control of autoimmunity to halt the destruction of beta-cells in the pancreas and restoration of beta-cell mass. We have built on the success of preclinical and clinical trials of anti-CD3 antibody treatment in modulating the immune response of T1D by the induction of tolerance and combined this treatment, using the nonobese diabetic mouse model, with a transplantation approach using fetal pancreatic anlagen as a source of beta-cell precursor or progenitor cells. Here we report that transplantation of pancreatic anlagen into diabetic nonobese diabetic mice rendered tolerant to the autoimmune process by treatment with anti-CD3 antibody resulted in long-term recovery from diabetes with restored metabolic control. Using a green fluorescent protein marker that made it possible to unequivocally identify the cells derived from the transplanted tissue, we show that the transplanted anlagen cells migrate to the host pancreas and provide a major source of insulin leading to restoration of normal glucose tolerance. Our results contrast with other studies that showed restoration of endogenous islets after infusion of spleen cells in mice treated with Freund's complete adjuvant and suggest that pancreatic fetal tissue has a tropism for the pancreatic site. This study suggests a novel mechanism of beta-cell restoration by the migration of precursor cells or their progeny to the host pancreas and highlights the feasibility of using pancreatic precursors in combination with immune modulation as a treatment to effect long-term remission of T1D.

Indexed as

Fetal Tissue TransplantationPancreas TransplantationAnimalsAntibodies, MonoclonalCD3 ComplexCell DifferentiationCell MovementDiabetes Mellitus, Type 1FemaleGreen Fluorescent ProteinsIslets of LangerhansMaleMiceMice, Inbred ICRMice, Inbred NODPancreasAntibodies, MonoclonalCD3 ComplexGreen Fluorescent Proteins

Identifiers

PMID19589867
PMCPMC2754682
OpenAlexW1984191777

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.